Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges... Show more
Centene Corporation operates as a leading healthcare enterprise focused on government-sponsored programs, including Medicaid, Medicare Advantage, and the Health Insurance Marketplace. Its core competitive advantages stem from deep expertise in these areas, a uniquely local approach to care delivery, and significant scale across all 50 states. This positioning enables tailored, culturally sensitive services that address social determinants of health, fostering member retention and provider relationships. The company’s diversification across business lines reduces reliance on any single segment while supporting expansion through geographic growth and strategic partnerships. Medium-term, Centene benefits from industry consolidation trends and its established infrastructure, though it faces ongoing competition and the need for continuous innovation in value-based care models.
The July 28, 2026, release of second-quarter results represents a near-term catalyst, with investors likely to scrutinize health benefits ratio trends and any updates on rate adequacy. Management’s recent upward revision of 2026 premium and service revenue guidance to $171.0 billion–$175.0 billion and adjusted diluted EPS to greater than $3.40 underscores improving operational visibility, particularly in Medicaid. Longer-term, potential regulatory decisions on Medicaid funding and Medicare Advantage bidding cycles could reshape reimbursement environments. Analyst rating revisions and consensus trends, if they shift toward greater optimism following earnings beats, may influence sentiment. Capital allocation decisions, such as share repurchases or targeted investments, also hold potential to affect valuation multiples.
The managed care sector remains sensitive to interest rate fluctuations, which affect Centene’s investment income, and inflation trends that can pressure medical and pharmacy costs. Healthcare policy developments, including potential changes to the Affordable Care Act or Medicaid expansion dynamics, directly influence membership and reimbursement levels. Consumer demand cycles tied to employment and economic conditions affect Marketplace enrollment, while broader adoption of technology supports efficiency gains. Regulatory climate around drug pricing and dual-eligible programs presents both opportunities for integrated care solutions and risks of margin compression if rates lag costs.
Tickeron’s Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality. For more details, visit the Trend Prediction Engine.
Looking to 2026 and beyond, Centene’s outlook centers on margin recovery in core Medicaid and Marketplace operations, supported by rate adjustments and membership stability. Long-term structural drivers include market expansion in Medicare Advantage and dual-eligible programs, alongside technology transitions that enhance care coordination and cost management. Margin sustainability will depend on effective medical cost controls and favorable policy environments. Competitive threats from peers and new entrants remain relevant, while regulatory developments could alter funding landscapes. Capital allocation priorities, including disciplined investments and potential returns to shareholders, may support earnings growth. Consensus analyst expectations, reflected in recent company guidance raises, suggest a measured path toward restored profitability if execution remains strong.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a multi-line healthcare enterprise
Industry ManagedHealthCare
A.I.dvisor indicates that over the last year, CNC has been closely correlated with MOH. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if CNC jumps, then MOH could also see price increases.
CNC's Aroon Indicator triggered a bullish signal on July 23, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 223 similar instances where the Aroon Indicator showed a similar pattern. In of the 223 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The Momentum Indicator moved above the 0 level on August 05, 2026. You may want to consider a long position or call options on CNC as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CNC just turned positive on August 07, 2026. Looking at past instances where CNC's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
CNC moved above its 50-day moving average on August 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CNC crossed bullishly above the 50-day moving average on August 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CNC advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CNC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.477) is normal, around the industry mean (3.842). P/E Ratio (9.063) is within average values for comparable stocks, (158.158). Projected Growth (PEG Ratio) (0.918) is also within normal values, averaging (1.253). CNC's Dividend Yield (0.000) is considerably lower than the industry average of (0.020). P/S Ratio (0.164) is also within normal values, averaging (0.593).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.